Correction: Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer

Lignende værker

• Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer
  af: Allouchery, Marion, et al.
  Udgivet: (2020)
• Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer
  af: Dolladille, Charles, et al.
  Udgivet: (2020)
• Biomarkers, Clinical Features, and Rechallenge for Immune Checkpoint Inhibitor Renal Immune-Related Adverse Events
  af: Isik, Busra, et al.
  Udgivet: (2021)
• Immune-Related Adverse Events (irAE) in Cancer Immune Checkpoint Inhibitors (ICI) and Survival Outcomes Correlation: To Rechallenge or Not?
  af: Albandar, Heidar J., et al.
  Udgivet: (2021)
• Immune Checkpoint Inhibitors and Immune-Related Adverse Renal Events
  af: Herrmann, Sandra M., et al.
  Udgivet: (2020)